SecBot SecBot
6-K ·Filed Apr 2, 2026

GLAXF

GSK plc
NEUTRAL
Impact 3/10
Horizonimmediate Processed6mo ago SEC0001654954-26-003197
Notable filing: 6-K
Actionable Insight • Neutral

This is a routine share buyback under a pre-announced program. While buybacks can support the stock price over time by reducing shares outstanding, this single day's activity is not material enough to significantly alter the investment thesis. Monitor the pace of future buybacks and overall capital allocation strategy.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d ⚠ clustered
GLAXF ▼ -5.31% at T+60d
NEUTRAL call -5.31% · α vs SPY -19.47% · entry $26.75 → $25.33
Entry = T+0 close
Apr 2, 2026
via day close
T+1d
-0.75%
call -0.75% · α -1.22%
$26.55
settled 7mo ago
T+5d
+9.35%
call +9.35% · α +5.73%
$29.25
settled 7mo ago
T+20d
-2.69%
call -2.69% · α -12.57%
$26.03
settled 6mo ago
T+60d
-5.31%
call -5.31% · α -19.47%
$25.33
settled 4mo ago

Price Chart

Loading chart...

Executive Summary

GSK plc repurchased 345,000 ordinary shares on April 1, 2026, at an average price of 2,106.14 GBp per share, as part of its ongoing buyback program. Since February 17, 2026, the company has bought back 16.57 million shares. This reduces the number of shares outstanding and increases the percentage of shares held in treasury to 6.32%.

Key Facts

  • GSK repurchased 345,000 ordinary shares on April 1, 2026
  • Average price paid: 2,106.14 GBp per share
  • Lowest price: 2,086.00 GBp, Highest price: 2,122.00 GBp
  • Part of an ongoing buyback program; 16,566,521 shares purchased since February 17, 2026
  • Following the purchase, 256,457,615 shares are held in treasury
  • Percentage of voting rights in treasury shares is now 6.32%

Financial Impact

The company spent approximately £7.27 million (345,000 shares * 2,106.14 GBp) on this repurchase, reducing its cash and increasing treasury stock on the balance sheet.

cashequityshares outstanding

Risk Factors

  • Routine buyback activity does not reflect on the company's underlying operational performance
  • The impact on earnings per share will be minimal given the small number of shares repurchased relative to the total outstanding

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-003197
Document: 0001654954-26-003197-index-headers.html0001654954-26-003197
Document: 0001654954-26-003197-index.html0001654954-26-003197
Document: 0001654954-26-003197.txt0001654954-26-003197
51 reports for GLAXF
Performance horizon
46% Hit rate @ T+5 6 of 13 directional calls Went positive at some point 7 of 13 best @ T+20▲ +9.49%Jun 9, 2026
Filters
Rows
Reports for GLAXF — sortable, filterable
TypeNow
Jun 10, 2026
19w ago
6-K
NEUTRAL ★ 1/10
$25.12 $25.25▲ +0.52%▼ −1.62%$26.12 (+3.98%)
Jun 9, 2026
20w ago
6-K
NEUTRAL ★ 1/10
$24.66 $25.50▲ +3.41%▲ +1.60%$26.12 (+5.92%)
Jun 9, 2026
20w ago
6-K
BULLISH ★ 7/10
$24.66 $25.50▲ +3.41%▲ +1.60%$26.12 (+5.92%)
Jun 1, 2026
21w ago
6-K
NEUTRAL ★ 1/10
$24.25 $24.66▲ +1.69%▲ +4.44%$26.12 (+7.71%)
Jun 1, 2026
21w ago
6-K
NEUTRAL ★ 2/10
$24.25 $24.66▲ +1.69%▲ +4.44%$26.12 (+7.71%)
May 28, 2026
21w ago
6-K
BULLISH ★ 7/10
$24.58 $24.66▲ +0.33%▲ +0.01%$26.12 (+6.27%)
May 27, 2026
21w ago
6-K
NEUTRAL ★ 1/10
$25.57 $23.94▼ −6.37%▼ −7.58%$26.12 (+2.15%)
May 26, 2026
22w ago
6-K
NEUTRAL ★ 1/10
$25.50 $24.25▼ −4.90%▼ −5.99%$26.12 (+2.43%)
May 26, 2026
22w ago
6-K
NEUTRAL ★ 2/10
$25.50 $24.25▼ −4.90%▼ −5.99%$26.12 (+2.43%)
May 22, 2026
22w ago
6-K
NEUTRAL ★ 2/10
$26.00 $24.25▼ −6.73%▼ −8.39%$26.12 (+0.46%)
Showing 10 of 51

US Market Status

Market Open — Closes in 1h 54m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 2, 2026